Source recordFED

Bally, Marcel B

Federal grants & contributions· Canadian Institutes of Health Research· FY2018· $489,600· BC

Description

Copper Drug Complexes: Development of a novel class of drugs with significant potential for treatment of platinum insensitive cancers

Amendment chain · 1 entry

Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header.

$489,600$0Original · 2017-04-01 (start date) · total $489,600
  • #02017-04-01$489,600
RowDateTotal value as of rowChange vs previousDescription on this row
#0 original2017-04-01(start date)$489,600—Copper Drug Complexes: Development of a novel class of drugs with significant potential for treatment of plati…

Related records · 2

Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).

Other current agreements for the same recipient (exact legal name match; no business number on file)

RefDepartment · programCurrent valueFY
236-2024-2025-Q3-00100Canadian Institutes of Health Research | Instituts de recherche en santé du Canada · Investigator-Initiated Research$1,028,926FY2025
236-2021-2022-Q3-00604Canadian Institutes of Health Research | Instituts de recherche en santé du Canada · Investigator-Initiated Research$765,000FY2022

Cite as: Glassbox record view · Federal grants & contributions · 236-2017-2018-Q1-00580 · retrieved 2026-11-15.